Genenta Science SPA (GNTA) Stock Analysis
Verdict: AVOID
Binary clinical-stage bet on GBM gene therapy with strong current liquidity but a critical 12-month cash runway gap.
Investment score: 38/100
Analysis as of
Is Genenta Science SPA stock worth reviewing? The TradeMates thesis
Genenta is a pre-revenue clinical biotech with promising GBM data but failing financial runway that necessitates dilution within 9 months.
7-factor investment score
- Valuation: 45/100 (weight 20%)
- Financial Health: 30/100 (weight 15%)
- Technical Momentum: 50/100 (weight 15%)
- Earnings Quality: 20/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 65/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
Genenta Science SPA opportunities and risks
What speaks for GNTA
- Lead Candidate Differentiation
What speaks against GNTA
- Critical Cash Runway Deficiency
Peers and competitors
- PHIL.MI
- ARBS.MI
Frequently asked questions about Genenta Science SPA (GNTA)
Is GNTA stock a good investment?
The TradeMates model rates Genenta Science SPA as AVOID with an investment score of 38/100. Genenta is a pre-revenue clinical biotech with promising GBM data but failing financial runway that necessitates dilution within 9 months. This is algorithmic model output, not personal investment advice.
Is GNTA stock a buy?
The TradeMates model verdict for GNTA is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.